BioCentury | Jul 28, 2016
Tools & Techniques

Innate harmony

...cell therapies in clinical and preclinical development (see Figure: Natural death). The most advanced product, CNDO-109-Activated...
...endogenous cells. Source: BCIQ: BioCentury Online Intelligence; company websites Cell Therapy Fortress Biotech Inc. (NASDAQ:FBIO). CNDO-109...
BioCentury | Oct 21, 2013
Analyst Picks & Changes

Analyst picks & changes

...to $3 from $13 and now views CNDO-109 as the primary value driver for Coronado. CNDO-109...
...testing for acute myelogenous leukemia (AML). Marai expects Coronado to begin Phase IIb testing with CNDO-109...
BioCentury | Dec 10, 2012
Clinical News

CNDO-109: Phase I/II started

...I/II trial to evaluate single infusions of low- and high-dose allogeneic NK cells activated by CNDO-109...
...36 AML patients in first complete remission and who are deemed high risk for relapse. CNDO-109...
...Drug designation in the U.S. to treat AML. Coronado Biosciences Inc. (NASDAQ:CNDO), Burlington, Mass. Product: CNDO-109...
BioCentury | Jun 25, 2012
Clinical News

CNDO-109 regulatory update

...FDA granted Orphan Drug designation for Coronado's CNDO-109 to treat acute myelogenous leukemia (AML). Next half...
...company plans to start a dose-escalation Phase I/II trial to evaluate the product for AML. CNDO-109...
...a biologic that activates natural killer (NK) cells. Coronado Biosciences Inc. (NASDAQ:CNDO), Burlington, Mass. Product: CNDO-109...
BioCentury | Jan 16, 2012
Finance

IPO end around

...following colonization of the host intestinal tract. The second is a Phase I/II trial of CNDO-109...
BioCentury | Jan 9, 2012
Clinical News

CNDO-109: Phase I final data

...evaluable patients experienced a longer subsequent complete response after receiving a single IV infusion of CNDO-109...
...1 patient who was in partial relapse reverted to a complete response following treatment with CNDO-109...
...At 24 hours after completing total body irradiation, patients received 1 million activated haploidentical-related donor CNDO-109...
BioCentury | Aug 1, 2011
Finance

Path less traveled

...following colonization of the host intestinal tract. Next is a planned Phase I/II trial of CNDO-109...
BioCentury | Nov 5, 2010
Financial News

Coronado raises $21.6 million

...CNDO-109, is slated to begin Phase II testing for acute myelogenous leukemia (AML) next year. CNDO-109...
Items per page:
1 - 8 of 8